David Nikodem, Ph.D.
Managing Director and Head of Biopharma Investments, Ally Bridge Group

Dr. Nikodem has over 15 years of investment experience as an investor with a global investment focus across all healthcare subsectors. He currently manages the BioPharmaceutical team at Ally Bridge Group, a Hong Kong based investment fund focused on Healthcare. Previously, David had been responsible for portfolio construction, risk management and all portfolio decisions for Exane Asset Management’s Equinox Fund in Paris, as well as on BNP Paribas’ proprietary desk in New York. Prior to healthcare investing, David worked as a patent examiner at the United States Patent & Trademark Office and as a basic science researcher at the National Institutes of Health. Dr. Nikodem holds a Ph.D. in Biochemistry and Molecular Biology from Georgetown University and a BA in Chemistry from The University of Virginia.